SpringWorks Therapeutics (SWTX) and Jennifer Fisher are collaborating to increase understanding of desmoid tumors as well as to encourage patients to find a specialist, like an oncologist with experience treating desmoid tumors who can discuss available treatment options to manage their desmoid tumor.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- Springworks Therapeutics (SWTX) Q4 Earnings Cheat Sheet
- SpringWorks Therapeutics price target raised to $87 from $65 at BofA
- SpringWorks Therapeutics CEO sells $2.56M in common stock
- Biotech Alert: Searches spiking for these stocks today
- Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon